Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ARGX with free AI briefings, catalyst countdowns, and dilution alerts.

ARGX · ARGENX SE

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$5.2B Cash on Hand
CF+ Cash Runway
2.3% Short Interest
$1150.61 Analyst Target (23)
Follow ARGX by email Get an email when ARGX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ARGX, unsubscribe in one click. Privacy

💊 Upcoming FDA Decisions

PDUFA DateDrugIndicationTypePoAOptions-implied move
2027-02-18 efgartigimod pediatric generalized myasthenia gravis sBLA 88% ±17% by Feb 19

Options-implied move = price of the at-the-money straddle for the first option expiry after the PDUFA date, as a share of the stock price (Yahoo Finance quotes, Nov 17). It prices every move until that expiry, not only the FDA decision.

PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →

📣 What ARGX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Efgartigimod Alfa
FDA approved Dec 2021 · Vyvgart
Myasthaenia Gravis Phase 3 · NCT06765161 Recruiting
EFG PH20 SC Active Idiopathic Inflammatory Myopathy Phase 2/3 · NCT05523167 Completed
Empasiprubart Multifocal Motor Neuropathy (MMN) Phase 3 · NCT06742190 Active not recruiting
Empasiprubart IV Chronic Inflammatory Demyelinating Polyneuropathy Phase 3 · NCT07091630 Recruiting
Efgartigimod PH20 (ARGX-113) SC Primary Sjogrens Disease Phase 3 · NCT06684847 Active not recruiting
Efgartigimod IV or Efgartigimod PH20 SC Generalized Myasthenia Gravis Phase 2/3 · NCT05374590 Enrolling by invitation
Efgartigimod IV Primary Immune Thrombocytopenia (ITP) Phase 3 · NCT06544499 Recruiting
IVIg Chronic Inflammatory Demyelinating Polyneuropathy Phase 3 · NCT06920004 Recruiting
Adimanebart IV Congenital Myasthenic Syndrome Phase 3 · NCT07746089 Not yet recruiting
ARGX-121 Immunoglobulin A Nephropathy (IgAN) Phase 2 · NCT07773727 Recruiting
Immunoglobulin Guillain-Barré Syndrome (GBS) Phase 2 · NCT07821762 Not yet recruiting
Cusatuzumab Leukemia, Myeloid, Acute Phase 2 · NCT04023526 Active not recruiting
Anti-MuSK Agonistic Monoclonal Antibody ARGX-119 Spinal Muscular Atrophy (SMA) Phase 2 · NCT07287982 Recruiting
ARGX-117 Delayed Graft Function Phase 2 · NCT05907096 Active not recruiting
empasiprubart SC AI Healthy Volunteers Phase 1 · NCT07612020 Recruiting
Efgartigimod PH20 SC via PFS Healthy Volunteer Phase 1 · NCT07782775 Completed

Also used in these trials (approved or third-party drugs, not ARGX's own candidates): Azacitidine, Venetoclax.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ARGX holds $5.2B in cash and short-term investments and its operations are currently cash-flow neutral or positive.

Dilution pressure: 8 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ARGX files for a raise →

👥 Who Owns ARGX

Insiders Form 4 data not loaded yet Institutions (762 holders) 46.3% Public and other holders 53.7%
HolderTypeShares% of sharesAs of
FMR LLC Institution (13G, 5%+) 6,178,792 9.98% 2026-09-30
Janus Henderson Group Ltd. Institution (13F) 2,391,136 3.86% 2026-09-30
Capital World Investors Institution (13F) 2,279,203 3.68% 2026-09-30
Price (T.Rowe) Associates Inc Institution (13F) 2,239,720 3.62% 2026-09-30
Artisan Partners Limited Partnership Institution (13F) 1,165,747 1.88% 2026-09-30
Avoro Capital Advisors LLC Institution (13F) 1,000,000 1.62% 2026-09-30
Blackrock Inc. Institution (13F) 879,255 1.42% 2026-09-30
Wellington Management Group, LLP Institution (13F) 715,939 1.16% 2026-09-30
RTW Investments LP Institution (13F) 711,584 1.15% 2026-09-30
Morgan Stanley Institution (13F) 586,527 0.95% 2026-09-30

Share count 61,883,306 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ARGX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ARGX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.